FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
#FDA #Wegovy #Novo Nordisk #weight loss drug #market share #higher dose #approval
📌 Key Takeaways
- FDA approved a higher dose version of Wegovy for weight loss.
- Novo Nordisk aims to regain market share with this new dosage.
- The approval addresses supply issues and competition in weight loss drugs.
- Higher dose may offer improved efficacy for patients.
📖 Full Retelling
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
🏷️ Themes
Pharmaceuticals, Weight Loss
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
Read full article at source